Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Calidi Biotherapeutics, founded in 2014 and headquartered in San Diego, California, is a clinical-stage immuno-oncology biotechnology company. We specialize in developing cell-based oncolytic virus immunotherapies for cancer treatment, offering an allogeneic stem cell and oncolytic virus combination for multiple oncology indications. The company has raised approximately $28.35 million in funding to date, demonstrating investor interest in its innovative approach to cancer therapy.
As a private company, Calidi Biotherapeutics' stock is not currently available for public trading. However, investors interested in the biotechnology sector often monitor companies like Calidi Biotherapeutics for potential investment opportunities. It's important to note that we do not have any confirmed information about Calidi Biotherapeutics' IPO plans or prospects at this time.
The decision to go public depends on various factors, including market conditions, company growth, and strategic objectives. For biotechnology companies like Calidi Biotherapeutics, factors such as clinical trial progress, regulatory approvals, and partnerships with larger pharmaceutical companies can also play a significant role in determining IPO readiness.
Investors interested in Calidi Biotherapeutics should continue to monitor official company announcements and industry news for any updates regarding potential IPO plans. As with any investment decision, it's crucial to conduct thorough research and consider the risks associated with investing in early-stage biotechnology companies.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Calidi Biotherapeutics' IPO prospects remain uncertain, investors eager to explore opportunities in the innovative biotherapeutics sector don't have to wait. At Linqto, we offer members access to interests in promising private companies before they go public. Our platform provides the opportunity to invest in potential leaders in the biotech industry, like Calidi Biotherapeutics, with lower minimum investments than traditional private equity opportunities. This allows you to potentially benefit from the growth of cutting-edge companies in the healthcare space before they hit the public markets.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
